about
When should MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes) be the diagnosis?Metabolomics Reveals New Mechanisms for Pathogenesis in Barth Syndrome and Introduces Novel Roles for Cardiolipin in Cellular FunctionRestoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation.The neuro-ophthalmology of mitochondrial diseaseThe effect of citrulline and arginine supplementation on lactic acidemia in MELAS syndrome.Genetic stroke syndromesMetabolically induced heteroplasmy shifting and l-arginine treatment reduce the energetic defect in a neuronal-like model of MELAS.Nitric oxide in skeletal muscle: role on mitochondrial biogenesis and function.Impaired nitric oxide production in children with MELAS syndrome and the effect of arginine and citrulline supplementation.Review of clinical trials for mitochondrial disorders: 1997-2012.Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.Multiple neurologic, psychiatric, and endocrine complaints in a young woman: a case discussion and review of the clinical features and management of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke.Case report: 5 year follow-up of adult late-onset mitochondrial encephalomyopathy with lactic acid and stroke-like episodes (MELAS).Treatment options for mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome.Mitochondrial disease and epilepsy.Stroke and Stroke-Like Symptoms in Patients with Mutations in the POLG1 GeneNitric oxide synthesis is increased in cybrid cells with m.3243A>G mutation.Inborn Errors of Metabolism and Epilepsy: Current Understanding, Diagnosis, and Treatment Approaches.Decreased exhaled nitric oxide levels in patients with mitochondrial disordersArginine improves peroxisome functioning in cells from patients with a mild peroxisome biogenesis disorder.Therapies for mitochondrial diseases and current clinical trials.Metabolic and chemical regulation of tRNA modification associated with taurine deficiency and human disease.Arginine and citrulline for the treatment of MELAS syndrome.
P2860
Q26777744-97F610C3-7852-4CCE-A4EF-D1106FD3F7B6Q28390562-32A0D4B7-C0A3-4484-B34F-39EA1ADEE818Q33887449-71D1041D-9DD2-49D1-AA52-2DBDADB93047Q34338783-5F911F6D-06E8-40A8-AC10-BBA83366A9E6Q34380418-23D2C893-7E26-471E-8BCE-1B23717011F5Q34522989-19393936-E263-46CC-866F-3F935C5BC144Q35919630-7896F0F5-1C15-4A42-80FD-E2973BAC7F7EQ36538574-D37BBA3A-8730-4ABC-8622-65A020102ADEQ36759443-0A73316D-37AB-44BB-9EA7-D31DD5F02B0EQ36762846-57F31A06-F6C6-40E8-AFAB-14988DC38A49Q37210464-29B42821-8F02-4148-B213-24EAE4AB115CQ37211810-9DC8604E-E411-4A6F-8E30-751E1DC4E68DQ37433521-058B4CDC-8438-4E42-A26B-28EBD903B596Q37802890-343808EE-AB76-425A-92F9-3BD16854E81EQ37979255-24942AD2-CB81-478C-A0FA-B06B8B4B0EF5Q38083635-077D8248-F9D2-40CD-BD52-F18FC394C4B7Q39221589-93A22ABF-7232-440F-9246-C9E92F84E259Q39411002-4F1F3737-B2BA-4EBF-8F33-6FF924E18AB7Q41811395-17551853-3B34-434C-8F2E-8B59662B6000Q42859596-85988277-17D8-407A-9A12-AC98C78CFAD6Q45872396-E7EB45F6-1A01-4FD9-B7C2-EB446907C8B5Q47640677-DEA61E71-8627-4153-8B37-08421B9810CBQ55036888-1C78F3B1-1DF6-4D8A-8D7E-73931F41B4CB
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
MELAS and L-arginine therapy
@ast
MELAS and L-arginine therapy
@en
MELAS and L-arginine therapy
@nl
type
label
MELAS and L-arginine therapy
@ast
MELAS and L-arginine therapy
@en
MELAS and L-arginine therapy
@nl
prefLabel
MELAS and L-arginine therapy
@ast
MELAS and L-arginine therapy
@en
MELAS and L-arginine therapy
@nl
P2093
P3181
P1433
P1476
MELAS and L-arginine therapy
@en
P2093
Junko Nishioka
Koujyu Katayama
Nataliya Povalko
Shuichi Yatsuga
Toyojiro Matsuishi
Yukihiro Akita
P304
P3181
P356
10.1016/J.MITO.2006.11.006
P407
P50
P577
2006-12-05T00:00:00Z